Clinical Technique

A Provider's Guide to Comparing FDA-Approved Botulinum Toxin Neuromodulators

A clinical comparison of FDA-approved botulinum toxin type A products for injectors: mechanism, formulation, dosing, onset, and duration.

A Provider's Guide to Comparing FDA-Approved Botulinum Toxin Neuromodulators

FAI Staff

FACE Aesthetic Institute

8 min read

Five botulinum toxin type A products currently hold FDA approval for aesthetic indications in the United States: onabotulinumtoxinA (Botox Cosmetic), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau), and daxibotulinumtoxinA (Daxxify). All five share the same core mechanism of action, but they differ meaningfully in formulation, dosing units, onset, and duration of effect. For injectors and trainees, understanding these distinctions is not academic. It directly affects dosing accuracy, patient counseling, and safe product substitution.

This guide summarizes what the prescribing information and published clinical data tell us about each product, with an emphasis on the practical decisions providers face at the point of care.

Shared Mechanism, Distinct Molecules

All five products are derived from Clostridium botulinum toxin type A and work by the same fundamental mechanism. The 150 kDa neurotoxin cleaves SNAP-25 (synaptosomal-associated protein of 25 kDa), a protein required for the docking and fusion of acetylcholine-containing vesicles at the presynaptic neuromuscular junction. By preventing SNAP-25-mediated vesicle fusion, the toxin blocks acetylcholine release, producing temporary chemodenervation and flaccid paralysis of the injected muscle.

Because all five agents target SNAP-25, their fundamental mechanism does not distinguish them clinically. What differs is everything around the core toxin: the manufacturing process, the presence or absence of accessory proteins, the stabilizing excipients, and the resulting potency units, onset, and duration.

Formulation Differences: Complexing Proteins and Excipients

Botulinum toxin is produced naturally as a large protein complex consisting of the 150 kDa neurotoxin bound to non-toxic accessory proteins (hemagglutinins and non-hemagglutinin proteins), sometimes called complexing proteins. How much of this complex remains in the final formulation varies by product.

  • OnabotulinumtoxinA (Botox Cosmetic): Formulated as part of an approximately 900 kDa complex, the largest of the group, along with human albumin and sodium chloride as stabilizers.
  • AbobotulinumtoxinA (Dysport): Formulated at a lower complex size, generally cited around 500 to 700 kDa, with human albumin and lactose as excipients.
  • IncobotulinumtoxinA (Xeomin): Manufactured to remove the complexing proteins entirely during purification, leaving only the 150 kDa "naked" core neurotoxin, formulated with human albumin and sucrose. Merz has marketed this as reducing exogenous protein load, though clinical significance regarding immunogenicity remains debated in the literature.
  • PrabotulinumtoxinA (Jeuveau): Also a 900 kDa complex similar in size to onabotulinumtoxinA, using a proprietary Hi-Pure manufacturing process, formulated with human albumin and sucrose.
  • DaxibotulinumtoxinA (Daxxify): The newest formulation approach. Instead of human albumin or animal-derived stabilizers, Daxxify uses Revance's proprietary Peptide Exchange Technology, a synthetic, positively charged 35-amino-acid excipient peptide (RTP004) that binds the toxin and promotes stability without complexing proteins, animal products, or human serum albumin. The FDA label lists each vial as containing daxibotulinumtoxinA-lanm, L-histidine, L-histidine HCl monohydrate, polysorbate 20, RTP004 peptide, and trehalose dihydrate.

The clinical relevance of complexing proteins to antigenicity and secondary non-response remains an active area of research, and no formulation has been shown in head-to-head trials to eliminate antibody risk. Injectors should treat formulation differences as a factor in the immunogenicity conversation, not a settled advantage for any single product.

FDA Approval History

ProductGeneric NameInitial FDA ApprovalAesthetic Approval Milestone
Botox CosmeticonabotulinumtoxinA1989 (therapeutic)April 12, 2002 (glabellar lines)
DysportabobotulinumtoxinAApril 29, 20092009 (glabellar lines, concurrent)
XeominincobotulinumtoxinAJuly 30, 2010 (therapeutic)July 21, 2011 (glabellar lines)
JeuveauprabotulinumtoxinA-xvfsFebruary 1, 2019February 1, 2019 (glabellar lines)
DaxxifydaxibotulinumtoxinA-lanmSeptember 8, 2022September 8, 2022 (glabellar lines)

Botox Cosmetic has since expanded to include forehead lines and lateral canthal lines (crow's feet), and Xeomin received approval in 2024 for simultaneous treatment of glabellar, forehead, and lateral canthal lines. Providers should always confirm a product's current approved indications against the most recent FDA label, since supplemental approvals continue to be added over time.

Dosing Units Are Not Interchangeable

This is one of the most important safety points for any injector, especially those cross-training across brands. Potency units for each botulinum toxin product are determined by product-specific, proprietary potency assays. A unit of one product's biological activity is not equivalent to a unit of another. The FDA-approved labeling for each product explicitly states that units are not interchangeable and that published conversion ratios from other formulations do not apply.

The clearest illustration is the FDA-approved glabellar line dosing for each product:

  • Botox Cosmetic: 20 units (4 units per site, 5 sites)
  • Dysport: 50 units (10 units per site, 5 sites)
  • Xeomin: 20 units (4 units per site, 5 sites)
  • Jeuveau: 20 units (4 units per site, 5 sites)
  • Daxxify: 40 units (8 units per site, 5 sites)

The commonly cited clinical conversion ratio of roughly 1 unit of onabotulinumtoxinA to 2.5 to 3 units of abobotulinumtoxinA is a practical heuristic drawn from comparative dosing studies, not an FDA-recognized equivalency. IncobotulinumtoxinA and prabotulinumtoxinA are generally dosed on an approximately 1:1 basis with onabotulinumtoxinA in clinical practice, reflecting their similar potency labeling units, but this is also not a formally established regulatory conversion. Daxxify's unit system is unique to its own potency assay and should not be estimated by analogy to any other product. Providers switching a patient between brands must dose according to that product's own labeling and clinical judgment, not a mental math shortcut.

Onset and Duration Differences

Reported onset and duration vary across products, based on prescribing information and pivotal trial data. These figures represent typical ranges reported in labeling and trials; individual patient response varies with dose, muscle mass, and injection technique.

  • Botox Cosmetic: Onset typically within 24 to 48 hours, with visible effect within one week. Duration of effect in glabellar line trials was generally up to 3 to 4 months.
  • Dysport: Onset reported as early as 2 to 3 days in some studies. Duration comparable to onabotulinumtoxinA, generally 3 to 4 months.
  • Xeomin: Onset similar to Botox Cosmetic, typically within a few days to one week. Duration also generally in the 3 to 4 month range.
  • Jeuveau: Pivotal trials (EV-001 and EV-002) followed subjects through Day 150, with responder rates (at least a 2-point improvement on the Glabellar Line Scale) of 67.5% and 70.4% versus placebo at Day 30. Labeling reflects effects lasting up to approximately 3 to 4 months, consistent with the 20-unit dose class.
  • Daxxify: Distinguished by longer duration in its pivotal SAKURA 1 and SAKURA 2 phase 3 trials. Median duration of response (return to none or mild glabellar line severity) was approximately 24 weeks (about 6 months) at the 40-unit dose, with some patients maintaining investigator-rated improvement out to 9 months. Onset in trial data began within 1 to 4 days for many patients, with peak effect around day 14.

Daxxify's extended duration is attributed to its peptide-stabilized formulation rather than a difference in its SNAP-25 mechanism, and it represents the most significant duration differentiation among the five products currently approved.

Practical Considerations for Product Selection

Choice of neuromodulator in practice is rarely about superiority of one product over another. It is about matching product characteristics to the patient and the practice setting.

  • Dosing familiarity and unit conversion risk. Practices that stock multiple brands must have clear, written dosing protocols to prevent unit confusion, particularly for staff who float between products.
  • Patient-specific factors. Patients with a history of secondary non-response (suspected neutralizing antibody formation) to one product may be candidates for a trial of an alternative formulation, though evidence for cross-reactivity avoidance is limited and individualized.
  • Duration expectations. Daxxify's longer labeled duration may appeal to patients seeking fewer annual visits, but it requires the same counseling rigor about onset timeline and touch-up expectations as any other product.
  • Reconstitution and storage protocols. Each product has distinct manufacturer guidance on reconstitution volume, storage temperature, and shelf life after reconstitution. These are not interchangeable across brands and must be followed per that product's prescribing information.
  • Cost and market factors. Acquisition cost per unit, patient loyalty programs, and regional pricing can influence practice-level product selection independent of clinical performance.
  • Manufacturer training. Each manufacturer offers product-specific injector training and clinical support resources. New injectors should complete brand-specific training before administering any product they have not been formally trained on.

Key Takeaways for Injectors

All five FDA-approved botulinum toxin type A products work through SNAP-25 cleavage at the neuromuscular junction, but they are distinct biologic drug products, not generic equivalents of one another. Formulation (complexing proteins versus purified core toxin versus peptide-stabilized), potency units, and clinical duration data all differ by product and are documented in each drug's individual FDA-approved prescribing information. Providers should never assume unit-for-unit interchangeability between brands and should always dose according to the specific product's current labeling and their own supervised clinical training.

Sources

  • U.S. Food and Drug Administration. BOTOX (onabotulinumtoxinA) Prescribing Information. accessdata.fda.gov
  • U.S. Food and Drug Administration. DYSPORT (abobotulinumtoxinA) Prescribing Information, Initial U.S. Approval 2009. accessdata.fda.gov
  • U.S. Food and Drug Administration. XEOMIN (incobotulinumtoxinA) Prescribing Information. accessdata.fda.gov
  • U.S. Food and Drug Administration. JEUVEAU (prabotulinumtoxinA-xvfs) Prescribing Information, BLA 761085. accessdata.fda.gov
  • U.S. Food and Drug Administration. DAXXIFY (daxibotulinumtoxinA-lanm) Prescribing Information, BLA 761127. accessdata.fda.gov
  • Bellows S, Jankovic J. "Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?" Biologics: Targets and Therapy / PMC3010823.
  • Carruthers A, et al. "DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from SAKURA 1 and SAKURA 2." Journal of the American Academy of Dermatology.

Educational Disclaimer

This article is intended for professional educational purposes for licensed healthcare providers and students in aesthetic medicine training programs. It is not a substitute for manufacturer-specific injector training, hands-on supervised clinical practice, or the current FDA-approved prescribing information for any product discussed. Providers must complete appropriate certification and hands-on training before administering any botulinum toxin product and should always consult the most current full prescribing information for dosing, contraindications, and safety data.

Tagged#botulinum toxin comparison for injectors#neuromodulator dosing conversion#onabotulinumtoxinA vs abobotulinumtoxinA#incobotulinumtoxinA complexing proteins#Daxxify peptide technology#choosing a neurotoxin brand

Written by

FAI Staff

Meet the faculty